Abstract
Despite two years of intense global research activity, host genetic factors that predispose to a poorer prognosis of COVID-19 infection remain poorly understood. Here, we prioritise eight robust (e.g., ELF5) or suggestive but unreported (e.g., RAB2A) candidate protein mediators of COVID-19 outcomes by integrating results from the COVID-19 Host Genetics Initiative with population-based plasma proteomics using statistical colocalisation. The transcription factor ELF5 (ELF5) shows robust and directionally consistent associations across different outcome definitions, including a >4-fold higher risk (odds ratio: 4.88; 95%-CI: 2.47-9.63; p-value < 5.0 × 10^-6) for severe COVID-19 per 1 s.d. higher genetically predicted plasma ELF5. We show that ELF5 is specifically expressed in epithelial cells of the respiratory system, such as secretory and alveolar type 2 cells, using single-cell RNA sequencing and immunohistochemistry. These cells are also likely targets of SARS-CoV-2 by colocalisation with key host factors, including ACE2 and TMPRSS2. In summary, large-scale human genetic studies together with gene expression at single-cell resolution highlight ELF5 as a risk gene for severe COVID-19, supporting a role of epithelial cells of the respiratory system in the adverse host response to SARS-CoV-2.
Introduction
While clinical risk factors like age and obesity are well-known, the "host genetics"—the specific variations in our DNA that predispose some individuals to life-threatening COVID-19—remain partially obscured. The primary challenge in this field is moving from association to causality. Genome-wide association studies (GWAS) often identify "risk loci" (regions of the genome), but these regions can contain multiple genes. Determining which specific gene is actually driving the disease is a massive hurdle. This study seeks to bridge that gap by linking genetic variants to protein levels in the blood and then to specific cell types in the lung.
Methods
The researchers employed a multi-layered "proteogenomic" approach to identify causal protein mediators.
The core analytical technique was statistical colocalization, which looked for overlapping genetic signals between COVID-19 severity (from the COVID-19 Host Genetics Initiative Release 6) and plasma protein levels (from the Fenland study, utilizing SomaScan v4 and Olink platforms). This was followed by Mendelian Randomization (MR) to estimate the effect of lifelong exposure to higher protein levels on COVID-19 outcomes. To move from systemic blood levels to tissue-specific mechanisms, the team utilized single-cell/nucleus RNA sequencing (sc/snRNA-seq) datasets from the respiratory system and validated findings via immunohistochemistry (IHC) on lung tissue from deceased COVID-19 patients.
Results
The prioritization pipeline identified eight candidate proteins, with ELF5 emerging as a novel, high-confidence lead.
Key findings include:
- Risk Magnitude: A 1 standard deviation increase in genetically predicted plasma ELF5 levels was associated with a 4.88-fold higher risk of severe COVID-19 (95% CI: 2.47–9.63).
- Candidate Prioritization: Other prioritized proteins included OAS1 (a known antiviral factor) and SFTPD (pulmonary surfactant protein D).
- Drug Target Identification: Genetically predicted higher levels of G-CSF (CSF3) were associated with a 25% reduction in the risk of severe COVID-19, providing genetic support for clinical trials using G-CSF.
Discussion
The transcription factor ELF5 showed a lung-specific genetic signal for COVID-19 risk. Single-cell analysis revealed that ELF5 is almost exclusively expressed in the "front line" cells of the respiratory system: secretory cells and Alveolar Type 2 (AT2) cells. These are the primary targets for SARS-CoV-2 entry. Furthermore, ELF5 expression correlates with TMPRSS2, a key protease used by the virus, suggesting ELF5 might regulate susceptibility.
Interestingly, the risk variant for COVID-19 was associated with better baseline lung function in healthy individuals. This suggests that while high ELF5 levels may support normal lung mechanics, they might lead to a maladaptive, hyper-responsive state during viral infection, similar to patterns seen in idiopathic pulmonary fibrosis.
Limitations
The study primarily used plasma protein levels as a proxy for ELF5 activity, which is a nuclear transcription factor. Plasma levels likely reflect cell turnover or lung injury rather than direct activity. Additionally, the proteomics data was largely derived from white British participants, necessitating validation in more diverse global populations. Finally, while the association is strong, the exact molecular mechanism by which ELF5 facilitates viral entry requires further experimental validation in cell models.
Summary updated